Covaxin Phase 3 Trial Result: 65.2% Efficacy Against Delta Variant, 77.8% Against Symptomatic COVID-19 Infection
Covaxin Phase 3 Trial Result: 65.2% Efficacy Against Delta Variant, 77.8% Against Symptomatic COVID-19 Infection Covaxin, India's indigenous COVID-19 vaccine, has concluded its final phase 3 trials and the results are out. Read on to know all about it. Written by Jahnavi Sarma | Published : July 3, 2021 12:19 PM IST Bharat Biotech has announced the safety and efficacy analysis data from Phase 3 clinical trials of Covaxin, its whole virion inactivated vaccine against SARS-CoV2, developed in partnership with ICMR and NIV Pune. According to the trial result, Covaxin is well tolerated and the Dat...
Source: thehealthsite.com